Alexander D. Guminski, MD, PhD, discusses the 12-month follow-up data from a phase II study investigating the role of cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.
Alexander D. Guminski, MD, PhD, a medical oncologist at the Royal North Shore Hospital in Australia, discusses the 12-month follow-up data from a phase II study investigating the role of cemiplimab (Libtayo) as a treatment for patients with metastatic cutaneous squamous cell carcinoma (mCSCC).
Fifty-nine patients with mCSCC were enrolled and received cemiplimab every 2 weeks on this trial. The median duration of follow-up for data presented at the 2019 ASCO Annual Meeting was 16.5 months. The primary endpoint was overall survival (OS). After seeing some maturity in the data for this follow-up, Guminski says there was a slight improvement in OS.
The overall response rate (ORR) was 49.2%. Of the 59 patients, 10 had achieved a complete response and 19 achieved a partial response. Median progression-free survival was 18.4 months, but the median OS had not yet been reached.
Guminski says that this is a group of pretreated patients where more than half had received at least 2 prior lines of therapy. Additionally, three-quarters of the patients also had distant visceral disease. This patient population is at a high risk of death from their malignancy, which makes these data very interesting.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More